RA Capital’s SPAC Merger Bet

The biopharma specialist could be signaling renewed confidence in the overall VC market.

Nicky Loh/Bloomberg

Nicky Loh/Bloomberg

There’s new hope for the flailing SPAC market.

The merger last week between the blank-check company Frazier Lifesciences Acquisition Corp. and the clinical-stage biopharma company NewAmsterdam Pharma Holding appears to be in much better financial shape than the usual post-SPAC deal these days.


To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.